How a Unity Health neurologist is rethinking stroke prevention for the longevity era
For decades, stroke prevention has revolved around a list of separate – and often separately treated – risk factors: blood pressure, cholesterol, diabetes, smoking and inactivity. According to Dr. Gustavo Saposnik, it’s time to start considering biological age as a risk factor for stroke.
The same biological processes associated with aging, including chronic inflammation and reduced cellular energy production, also drive conditions such as hypertension and diabetes and increase the risk of stroke. People may be living longer than ever before, but stroke is appearing in younger adults more frequently than in previous generations, and stroke incidence is also rising in older populations.
Saposnik, a neurologist and researcher at St. Michael’s Hospital, argues in a new paper that stroke is often not an isolated vascular event, but instead the first obvious sign that the body’s biological aging process is accelerating. To combat it we need to think about longevity.
“What longevity science adds is an organizing principle,” says Saposnik, who is also a professor of neurology at the University of Toronto, director of the Stroke Outcomes and Decision Neuroscience Research Unit at Unity Health Toronto, and vice-president of the World Stroke Organization.
“These are not ten separate battles but one, against the pace of biological aging. Your birthday tells your chronological age, but it is the status of the arteries that tell us how old you are and your risk of having a heart attack or stroke”.
Enjoying this story? Sign up for the Unity Health Toronto newsletter, a monthly update on the latest news, stories, patient voices and research emailed directly to subscribers.
Saposnik’s paper makes straightforward stroke prevention recommendations for patients and clinicians, encouraging them to focus on blood pressure control, Mediterranean-style diets, building in 150 minutes of aerobic exercise a week, getting at least 6 hours of resting sleep a night, lowering LDL cholesterol and appropriately treating heart rhythm disorders like atrial fibrillation.
At the same time, while biological-age testing, whole-body MRI screening and various longevity products have generated significant public interest, Saposnik cautions that evidence remains limited. Instead, he points to more established measures of vascular health, such as carotid and femoral artery plaque burden, which can provide tangible evidence of cardiovascular aging and future risk.
While Saposnik’s recommendations are fairly simple, he says medicine has often underestimated the role of human behaviour in health. The challenge is that prevention asks people to accept a cost today for a benefit they may not see for years. High blood pressure and high cholesterol are largely invisible until a serious event occurs.
Saposnik’s research is in decision neuroscience, examining how people weigh risk, reward and delay, and what actually moves them to act. He has found that information is rarely enough on its own. What tends to work is changing the environment in which the decision gets made, through what behavioural economists call nudges: a prescription written with a dose and a review date rather than general advice, a follow-up visit booked by default instead of left to the patient, a target blood pressure recorded where both doctor and patient can see it.
“We know what prevents strokes,” he says. “The harder question is what makes someone act on it.”

The same barriers affect clinicians. Saposnik points to what researchers call therapeutic inertia: the tendency to delay intensifying treatment even when risk factors remain uncontrolled.
“If I intensify treatment and my patient becomes dizzy and falls, that harm is immediate,” he said. “If I wait and they have a stroke in four years, the harm is deferred and belongs to no one.”
He believes health systems need to take behavioural science as seriously as biology. One practical step is encouraging patients to ask three simple questions: What is my target? Are we there? And when do we act if we’re not?
The paper, co-authored with Dr. Conrado Estol, a stroke neurologist from Argentina, also explores the growing role of wearable technology. Saposnik uses a smartwatch himself but is cautious about overstating its value. After receiving an atrial fibrillation alert during a flight that was later determined to be related to plane motion and vibration rather than an actual health event, he gained firsthand experience with the anxiety false alarms can create.
While no major trial has yet shown that smartwatch screening reduces stroke rates, he believes wearables can still be valuable if they encourage healthier habits.
Ultimately, the authors argue that the goal of stroke prevention should extend beyond avoiding a medical event and focus on helping people live more years free from disability, cognitive decline and loss of independence.
Saposnik is working to take his research and findings beyond academic journals, pursuing a journalism fellowship in hopes of translating clinical data, knowledge and expertise into something tangible that nudges people into action.
He is also working to create the Silent Infarction Prevention Clinic (SIC), which would build on his research to address stroke as a signal of biological aging.
“The outcome I would most like to see tracked is not strokes prevented but years lived without disability,” said Saposnik. “That’s the actual goal.”
The future of stroke prevention may not depend on discovering entirely new interventions, but on helping people act on the evidence we already have before stroke becomes the first sign that time is catching up with them.
By Olivia Lavery
